Medicare and HRT: What's Covered, What Costs, and How to Pay Less

Does Medicare Cover Hormone Replacement Therapy?

Medicare Part D covers FDA-approved HRT medications when they appear on your specific plan's formulary. Part A and Part B generally do not pay for self-administered hormone drugs, so the pharmacy benefit (Part D, or an equivalent Medicare Advantage drug benefit) is almost always where coverage lives. The 2025 Inflation Reduction Act out-of-pocket cap of $2,000 per year applies to all Part D drugs, including HRT, which limits catastrophic-phase spending for women on high-cost branded formulations.

The Centers for Medicare and Medicaid Services classifies menopausal hormone products under the "protected class" rules only for antidepressants, antiretrovirals, antipsychotics, anticonvulsants, immunosuppressants, and antineoplastics. HRT does not have protected-class status, which means Part D plans can restrict quantity, require step therapy, or exclude specific products entirely. CMS Part D formulary guidance confirms plans must cover at least two drugs in each therapeutic category, but HRT sits across multiple categories (estrogens, progestins, combinations), so one plan might cover the Vivelle-Dot patch but not the Climara patch. Checking the specific plan's formulary at Medicare.gov before enrolling is the single most reliable step a woman can take.

Bioidentical compounded HRT, widely prescribed by telehealth platforms, is not covered by Medicare Part D under any circumstance. FDA rules prohibit Medicare payment for compounded drugs that have an FDA-approved commercially available equivalent, and most compounded estradiol/progesterone formulations fall into that category per FDA compounding policy.

Which Specific HRT Drugs Does Medicare Part D Cover?

Most commercially manufactured, FDA-approved HRT products appear on at least some Part D formularies. Coverage tiers differ by plan, but the pattern below holds across the majority of national plans.

Oral estrogens and combinations: Generic estradiol 0.5 mg, 1 mg, and 2 mg tablets typically land on Tier 1 or Tier 2, meaning a 30-day supply costs $0, $20 after the deductible. Brand-name Bijuva (estradiol/progesterone 1 mg/100 mg oral capsule, approved by FDA in 2018) commonly sits at Tier 3 or Tier 4, with cost-sharing of $75, $175 per fill before catastrophic coverage kicks in. Prometrium (micronized progesterone 100 mg and 200 mg) is frequently on Tier 2 as a preferred brand, running $30, $60/month.

Patches: Generic estradiol patches (0.025 mg/day through 0.1 mg/day, twice-weekly and weekly formulations) are Tier 1 on many plans at $10, $30/month. Brand Vivelle-Dot and Climara appear on Tier 2, 3 at $45, $120/month. Combipatch (estradiol/norethindrone acetate) tends to be Tier 3 with prior authorization required.

Vaginal products: The Estring vaginal ring (estradiol 2 mg, 90-day) is covered on most plans at Tier 2; expect $60, $100 per ring (a 3-month supply). Vagifem (estradiol 10 mcg vaginal inserts) is Tier 2 on many plans, roughly $40, $90/month. Generic yuvafem vaginal inserts often land at Tier 1, under $30/month.

Gels and sprays: EstroGel 0.06% and Divigel estradiol gel are generally Tier 3, $80, $160/month. Evamist estradiol spray is Tier 3, 4 on most plans and often requires prior authorization. No widely available generics exist for these topical forms yet, which limits Tier 1 access.

A 2022 analysis published in JAMA Internal Medicine examining Medicare Part D spending found that estrogen-containing drugs represented one of the most cost-variable therapeutic categories across plan formularies, with beneficiary cost-sharing differing by as much as 400% for the same molecule depending on formulation and plan selection. That variation is reason enough to use Medicare's Plan Finder tool every October during open enrollment.

How Medicare Prior Authorization for HRT Works

Prior authorization (PA) is a formal requirement from your Part D plan that your prescriber document medical necessity before the plan will pay for a drug. Most PA requirements for HRT target brand-name or higher-tier products.

Typical PA criteria for brand-name HRT under Part D include:

1. Documentation of a menopause diagnosis (ICD-10 code N95.1 for menopausal or female climacteric states, or Z78.0 for asymptomatic menopausal status).
2. Proof that a generic or lower-tier alternative was tried and either failed or is medically inappropriate, sometimes called step therapy.
3. Prescriber attestation that the specific formulation (e.g., a patch vs. a tablet) is required due to gastrointestinal intolerance, skin sensitivity, or another documented clinical reason.

Your prescriber submits a PA request through the plan's portal or fax line. Plans must respond within 72 hours for standard requests or 24 hours for expedited requests, per CMS rules codified in 42 CFR Part 423. If denied, you have the right to a formulary exception appeal, then a redetermination, and ultimately an Independent Review Entity (IRE) review. The North American Menopause Society (NAMS) 2022 Position Statement states: "Hormone therapy remains the most effective treatment for vasomotor symptoms and is appropriate for healthy women under age 60 or within 10 years of menopause onset." That clinical statement is frequently used by prescribers as supporting documentation in PA appeals. Read the NAMS 2022 Position Statement at menopause.org.

Step therapy exceptions are important to understand. The 2018 Improving Seniors' Timely Access to Care Act, signed into law in 2022, requires Medicare Advantage plans (not standalone Part D) to have a transparent step-therapy exception process and respond to exception requests within 72 hours standard or 24 hours expedited. If your MA plan requires you to try an oral estrogen before approving a patch, and you have a documented history of nausea or elevated triglycerides on oral estrogens (a real pharmacokinetic concern, since oral estrogens undergo first-pass hepatic metabolism), your prescriber can cite that physiology to override the step requirement.

What HRT Actually Costs Monthly Under Medicare

Out-of-pocket costs under Part D follow a three-phase structure beginning in 2025 under the Inflation Reduction Act redesign.

Deductible phase: Most plans carry a deductible up to $590 in 2025. You pay 100% of drug costs until the deductible is met. For a woman whose only Part D drug is generic estradiol at $15/month, the deductible may never be reached.

Initial coverage phase: After the deductible, you pay your plan's copay or coinsurance per tier until your total drug spending reaches $2,000. Tier 1 generics run $0, $20 per fill; Tier 3 brands run $45, $100; Tier 4 non-preferred brands run $95, $175.

Catastrophic phase: Once you've paid $2,000 out of pocket in 2025 (counting manufacturer discounts), you pay $0 for the rest of the year. This is new for 2025 and eliminates the old 5% catastrophic coinsurance that hit women on expensive brand HRT hardest.

For women with incomes below 150% of the federal poverty level, the Low-Income Subsidy (Extra Help) program caps Tier 1, 2 copays at $4.50 and Tier 3, 5 copays at $11.20 in 2025. Applications go through the Social Security Administration at ssa.gov.

A 2023 Kaiser Family Foundation analysis found that roughly 3.4 million Medicare Part D enrollees used at least one menopausal hormone product, with median annual out-of-pocket spending of $84 for generic estrogens and $412 for brand-name combinations before the 2025 cap took effect. The $2,000 annual ceiling should reduce that brand-combination number meaningfully for the roughly 15% of HRT users who previously hit catastrophic thresholds. See KFF Medicare Part D data at kff.org.

Medicare Advantage vs. Standalone Part D for HRT Coverage

Medicare Advantage (MA) plans bundle Part A, Part B, and usually Part D into one plan. Their HRT formularies follow the same CMS minimum standards as standalone Part D but often add extra restrictions, including:

• Quantity limits (e.g., 30 patches per 60-day supply rather than per 30-day supply, which can create refill gaps)
• Preferred pharmacy networks that restrict where you can fill topical HRT
• More aggressive step-therapy requirements before allowing brand patches or gels

Standalone Part D plans attached to Original Medicare tend to have more predictable formulary structures, and you can use any pharmacy that accepts Medicare. For women who use brand-name patches or vaginal rings and see multiple specialists, Original Medicare plus a standalone Part D plan often produces lower total cost and fewer authorization hurdles than MA.

The best comparison strategy: use Medicare's Plan Finder at medicare.gov/plan-compare in October, enter your specific drug names and doses, and compare the estimated annual cost output across every plan available in your ZIP code. Do this each year; formularies change annually.

Online HRT Clinics and How They Compare to Medicare

Telehealth HRT platforms, including Midi, Alloy, Plushcare, Evernow, and Winona, operate almost entirely outside Medicare billing. They charge a monthly membership or visit fee ($20, $99/month) plus prescription costs, which you pay cash-pay or through commercial insurance.

Here is how the economics compare for a typical Medicare-age woman (65+) on estradiol + progesterone:

| Route | Monthly Rx Cost | Prescriber Fee | Notes | |---|---|---|---| | Medicare Part D, generic oral estradiol + Prometrium | $15, $60 | $0 (covered under Part B for physician visit) | Requires Part D enrollment | | Medicare Part D, brand patch (Vivelle-Dot) + Prometrium | $60, $150 | $0 | PA may be required | | Telehealth platform (e.g., Midi, Alloy) cash-pay | $75, $200 | $20, $99/month | No Medicare billing; compounded options available | | GoodRx / Mark Cuban Cost Plus on generics | $12, $45 | $0 if using existing prescriber | Cannot be combined with Medicare Part D in same transaction |

The table above reflects 2025 cash-pay and Part D benchmark pricing. Individual plan cost-sharing will vary.

One practical nuance: women who want compounded bioidentical HRT (e.g., a specific estradiol/estriol/progesterone troche or cream not commercially available) must pay entirely out of pocket because Medicare will not cover it and most commercial plans won't either. Telehealth platforms that specialize in compounded BHRT are therefore operating in a separate market. The FDA's position, stated in its 2020 draft guidance, is that compounding estrogens in doses or combinations that duplicate an FDA-approved product lacks clinical justification and raises safety concerns, though compounding pharmacies continue to operate under state oversight where no commercially available equivalent exists. FDA compounding position.

HRT Safety Evidence Relevant to Medicare-Age Women

Women in their 60s and 70s asking about HRT face a distinct evidence picture from younger women starting at menopause onset. The Women's Health Initiative (WHI) enrolled 16,608 postmenopausal women ages 50 to 79 and found that combined conjugated equine estrogen plus medroxyprogesterone acetate increased breast cancer risk after 5.6 years of use (hazard ratio 1.26 to 95% CI 1.00, 1.59) and increased cardiovascular events in women who were more than 10 years past menopause. Original WHI findings via NEJM.

The "timing hypothesis," supported by WHI Memory Study and the KEEPS trial (Kronos Early Estrogen Prevention Study, N=727), holds that estrogen started within 6 years of menopause onset does not increase cardiovascular risk and may be cardioprotective. Women initiating HRT at age 65 or older, particularly those more than 10 years past their final menstrual period, carry a different risk-benefit ratio. The Endocrine Society's 2022 clinical practice guideline states: "For women aged 60 years or older or more than 10 years past menopause, the benefit-risk ratio is less favorable and therapy should be individualized." Endocrine Society guideline at endocrine.org.

For Medicare beneficiaries, that individualization conversation happens with a physician, not a formulary. Medicare covers the prescriber visit; the formulary just determines which drug you can afford after the prescription is written.

Steps to Maximize Medicare HRT Coverage

Getting the best coverage outcome from Medicare requires a specific sequence of actions, not a general one.

Step 1. Run the formulary check before filling. At medicare.gov/plan-compare, enter your drug, dose, and dosing frequency. The tool returns your estimated annual cost under every plan in your area. Do this in October for the following year's coverage.

Step 2. Ask your prescriber to write for the generic first. Generic oral estradiol and generic micronized progesterone (Prometrium's generic is available) satisfy most step-therapy requirements and cost $10, $30/month each on Tier 1. If generics cause side effects, that clinical record supports a PA for brand alternatives.

Step 3. Request a formulary exception in writing if denied. Your prescriber completes a Coverage Determination Request citing the NAMS 2022 Position Statement, your symptom severity, and any contraindication to the plan's preferred alternative. Plans must decide within 72 hours.

Step 4. Apply for Extra Help if income qualifies. For 2025, single-person households earning below $22,590/year (150% FPL) qualify. This cuts most HRT copays to under $12/month regardless of tier.

Step 5. Compare GoodRx pricing at the time of fill. You cannot use GoodRx and Medicare Part D simultaneously on the same claim, but if your drug's GoodRx price is lower than your Part D cost-sharing, you can choose to pay cash-pay for that fill (the cost will not count toward your $2,000 out-of-pocket cap, however).

Step 6. If denied after appeal, file an IRE complaint. The independent review entity must issue a decision within 72 hours (expedited) or 7 days (standard). Approval rates at IRE review for medically documented HRT needs are not publicly reported at the plan level, but CMS data show that roughly 40% of Medicare Part D appeals are resolved in the enrollee's favor at the redetermination stage alone.

Testosterone for Women Under Medicare

Low-dose testosterone for female hypoactive sexual desire disorder (HSDD) or general androgen deficiency is prescribed off-label in the United States because no FDA-approved testosterone product exists for women. Medicare Part D does not cover off-label drug use unless the drug appears in one of CMS's approved compendia (e.g., DrugDex, Clinical Pharmacology) for that indication. Testosterone for women does not appear in those compendia for HSDD. Women who want testosterone therapy typically pay $30, $80/month cash-pay for compounded testosterone cream or gel, entirely outside Medicare.

The Endocrine Society's 2019 position paper on testosterone therapy in women, published in the Journal of Clinical Endocrinology and Metabolism, states that testosterone may improve sexual function in postmenopausal women but that long-term cardiovascular and breast safety data remain insufficient for routine prescription. That evidentiary gap is part of why FDA approval, and by extension Medicare coverage, has not materialized.

Frequently Asked Questions